With a market cap of $14.2 billion, Wilmington, Delaware-based Incyte Corporation (INCY) is a biopharmaceutical company specializing in developing therapies for oncology, hematology, and autoimmune diseases. The company’s key products include Jakafi for myelofibrosis and polycythemia vera, along with a diverse pipeline of innovative treatments. Companies valued at $10 billion or more are generally labeled as “large-cap” stocks, and Incyte fits this criterion perfectly. Incyte’s uniqueness lies in its specialization in developing breakthrough JAK inhibitors and groundbreaking small-molecule dru…